Growth Metrics

Day One Biopharmaceuticals (DAWN) Income towards Parent Company: 2023-2025

Historic Income towards Parent Company for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.

  • Day One Biopharmaceuticals' Income towards Parent Company fell 154.94% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.7 million, marking a year-over-year increase of 21.59%. This contributed to the annual value of -$204.7 million for FY2024, which is 8.38% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Income towards Parent Company of -$19.7 million as of Q3 2025, which was up 35.02% from -$30.3 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Income towards Parent Company high stood at $35.8 million for Q3 2024, and its period low was -$112.4 million during Q2 2024.
  • In the last 3 years, Day One Biopharmaceuticals' Income towards Parent Company had a median value of -$44.3 million in 2023 and averaged -$43.4 million.
  • Data for Day One Biopharmaceuticals' Income towards Parent Company shows a peak YoY increase of 177.66% (in 2024) and a maximum YoY decrease of 165.16% (in 2024) over the last 5 years.
  • Over the past 3 years, Day One Biopharmaceuticals' Income towards Parent Company (Quarterly) stood at -$54.5 million in 2023, then declined by 20.61% to -$65.7 million in 2024, then crashed by 154.94% to -$19.7 million in 2025.
  • Its last three reported values are -$19.7 million in Q3 2025, -$30.3 million for Q2 2025, and -$36.0 million during Q1 2025.